ReviewRespirology (Carlton, Vic.)2025
Lessons Learned From International Lung Cancer Screening Trials; People at Risk Deserve Screening for Early Detection.
Review in Respirology (Carlton, Vic.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reducing the burden of lung cancer through primary, secondary, tertiary and quaternary prevention.Singapore medical journal · 2025Article
- Lessons Learned From International Lung Cancer Screening Trials; People at Risk Deserve Screening for Early Detection.Respirology (Carlton, Vic.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In the modern era, the role of lung cancer screening by low dose computed tomography (CT) is now broadly accepted, with many jurisdictions offering or intending to offer population-based screening based on high quality randomised controlled trial (RCT) evidence. Optimal implementation will be crucial to ensure sufficiently high participation rates in efficient quality assured lung cancer screening programmes (LCSPs) to achieve the gains predicted by modelling and health technology assessments. Performed well, LCSPs can be anticipated to complement the reduction in lung cancer burden already realised from the introduction of molecularly targeted agents and immune checkpoint inhibitors for advanced stage lung cancer. In this review, we will describe the recent clinical developments from published trials to highlight contemporaneous lung cancer screening (LCS) issues and discuss potential enablers and barriers to the effective implementation of LCSP commonly encountered across the world, particularly from the viewpoint of the Asia Pacific region and peoples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.